ERBB2 and breast neoplasm: Therefore, overexpression of GSDMB is a novel therapeutic target for HER2 breast malignancies, and intracellular delivery of GSDMB antibody utilizing nanoparticles greatly reduced the growth and metastatic development of HER2 breast tumors.